Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.16
$1.87
$0.94
▼
$46.50
$8.10M2.85320,339 shs60,632 shs
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
$8.55
+0.7%		$7.38
$6.32
▼
$12.58
$34.38M1.0619,129 shs11,905 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$31.32
+2.5%		$25.11
$15.10
▼
$909.98
$31.07M1.3124,284 shs37,860 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.10
-2.3%		$3.30
$2.04
▼
$16.25
$31.16M1.5362,240 shs7,909 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-4.13%-23.18%-79.40%-88.24%
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
+0.71%+6.61%+22.32%+27.42%+854,999,900.00%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
+2.52%-7.20%+8.45%+55.05%-90.27%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
-2.33%-12.86%-24.46%-51.39%-61.82%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.16
$1.87
$0.94
▼
$46.50
$8.10M2.85320,339 shs60,632 shs
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
$8.55
+0.7%		$7.38
$6.32
▼
$12.58
$34.38M1.0619,129 shs11,905 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$31.32
+2.5%		$25.11
$15.10
▼
$909.98
$31.07M1.3124,284 shs37,860 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$2.10
-2.3%		$3.30
$2.04
▼
$16.25
$31.16M1.5362,240 shs7,909 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-4.13%-23.18%-79.40%-88.24%
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
+0.71%+6.61%+22.32%+27.42%+854,999,900.00%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
+2.52%-7.20%+8.45%+55.05%-90.27%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
-2.33%-12.86%-24.46%-51.39%-61.82%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.50
Moderate Buy$67.505,718.97% Upside
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
2.40
Hold$36.00321.05% Upside
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
2.42
Hold$260.00730.14% Upside
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
2.33
Hold$11.00423.81% Upside

Current Analyst Ratings Breakdown

Latest CODX, RADX, QNCX, and KYNB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/1/2026
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$43.00
8/27/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/26/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/20/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$68.00
8/18/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/18/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$70.00
8/14/2026
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
8/12/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/29/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/29/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$82.00
7/17/2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$721.39K11.23N/AN/A$1.82 per share0.64
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
$6.44M5.38N/AN/A($7.32) per share-1.17
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/A($34.73) per shareN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$1.88M16.15N/AN/A$1.05 per share2.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$46.90M-$10.32N/AN/AN/A-6,531.77%-210.99%-174.97%11/5/2026 (Estimated)
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
$183.45M$45.300.19N/AN/A2,199.13%N/A-47.27%N/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$83.98M-$156.71N/AN/AN/AN/AN/A-133.84%11/11/2026 (Estimated)
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
-$24.83MN/AN/AN/AN/AN/AN/AN/AN/A

Latest CODX, RADX, QNCX, and KYNB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$28.02-$12.31+$15.71-$12.31N/AN/A
8/13/2026Q2 2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$3.00-$1.46+$1.54-$1.46$0.13 million$0.17 million
7/31/2026Q4 2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A-$0.81N/A-$0.8050N/A$0.49 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
N/AN/AN/AN/AN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/AN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
1.81
1.52
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
N/A
2.69
2.59
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/A
14.52
14.52
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
1.16
N/A

Institutional Ownership

CompanyInstitutional Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
72.71%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
30.75%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A

Insider Ownership

CompanyInsider Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.30%
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
4.15%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
5.60%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
1006.98 million6.82 millionNo Data
Kyntra Bio Inc stock logo
KYNB
Kyntra Bio
5704.05 million3.88 millionN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
601.02 million960,000Optionable
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A14.46 millionN/AN/A

Recent News About These Companies

Radiopharm Theranostics Ltd ADR (RADX)
September 1, 2026  |  investing.comhttps://www.investing.com/equities/radiopharm-theranostics-adr-financial-summary
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351185/0/en/radiopharm-theranostics-doses-first-patient-in-second-cohort-of-phase-1-2a-clinical-trial-of-betabart-rv-01-in-b7-h3-expressing-solid-tumors.html
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348199/0/en/radiopharm-theranostics-receives-positive-recommendation-from-data-safety-and-monitoring-committee-to-advance-to-cohort-4-in-177lu-rad202-phase-1-heat-clinical-trial.html
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radiopharm-theranostics-meet-u-fda-113000466.html
RADX: RAD101 Topline & FY:26 Cash Flows
August 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/radx-rad101-topline-fy-26-151400375.html
Radiopharm Dips on Securities Pact
July 25, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23725/Radiopharm-Dips-on-Securities-Pact
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
July 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/24/3332785/0/en/radiopharm-theranostics-announces-concurrent-us-4-1-million-registered-direct-offering-and-up-to-additional-a-12-7-us-8-9-million-australian-placement-and-share-purchase-plan.html
Radiopharm Highlights Data Release
July 23, 2026  |  baystreet.cahttps://www.baystreet.ca/techinsider/5668/Radiopharm-Highlights-Data-Release
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331243/0/en/radiopharm-theranostics-achieves-confirmed-durable-partial-response-in-ongoing-phase-1-trial-of-rad204-in-patients-with-advanced-solid-tumors-post-immunotherapy.html
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331214/0/en/radiopharm-theranostics-announces-positive-phase-2b-trial-results-of-rad-101-for-diagnosis-of-brain-metastases.html
Radiopharm Theranostics Ltd ADR RADX
July 16, 2026  |  morningstar.comM
Radiopharm Theranostics Limited Sponsored ADR
May 14, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/RADX
RADX: Fiscal 3Q:26 Cash Flow Report
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/radx-fiscal-3q-26-cash-092400408.html
Radiopharm Theranostics Ltd. ADR
May 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/radx/financials
Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs
April 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/radiopharm-theranostics-adr-radx-inside-the-clinical-programs-1748993/
Radiopharm Theranostics Reports Business Update
April 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/23/3279721/0/en/radiopharm-theranostics-reports-business-update.html
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer ...
April 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/radiopharm-theranostics-presents-initial-findings-110000207.html
Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
April 16, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/radiopharm-theranostics-completes-enrollment-in-u-s-phase-2b-imaging-trial-of-rad-101-for-diagnosis-of-brain-metastases-1036028670
Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target increased by 752.98% to 39.26
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/radiopharm-theranostics-limited-depositary-receipt-radx-price-target-increased-by-752-98-to-39-26/ar-AA20YjrZ
Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target decreased by 11.04% to 4.60
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/radiopharm-theranostics-limited-depositary-receipt-radx-price-target-decreased-by-1104-to-460/ar-AA20utAZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Co-Diagnostics stock logo

Co-Diagnostics NASDAQ:CODX

$1.16 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Kyntra Bio stock logo

Kyntra Bio NASDAQ:KYNB

$8.55 +0.06 (+0.71%)
As of 09/4/2026 04:00 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Quince Therapeutics stock logo

Quince Therapeutics NASDAQ:QNCX

$31.32 +0.77 (+2.52%)
As of 09/4/2026 04:00 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Radiopharm Theranostics stock logo

Radiopharm Theranostics NASDAQ:RADX

$2.10 -0.05 (-2.33%)
As of 09/4/2026 03:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas